Advanced Solid Tumors Clinical Trials in New York, New York

24 studies are recruiting for advanced solid tumors in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

   The goal of this study is to learn if KQB368 works to treat advanced solid malignancies in adults. The study will also learn about the safety of KQB368. The main questions the study aims to answer are: * What is the safe dose of KQB368 as a monotherapy? * Does KQB368 decrease the size of the tumor?…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   14 in total

   Run by

   Kumquat Biosciences Inc.

   See if you can join NCT07542704 on ClinicalTrials.gov

2. EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

   The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York

   Locations

   45 in total

   Run by

   Eikon Therapeutics

   See if you can join NCT07262619 on ClinicalTrials.gov

3. A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

   A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies

   Stage

   Phase 1

   Ages

   16 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   6 in total

   Run by

   SEED Therapeutics, Inc.

   See if you can join NCT07197554 on ClinicalTrials.gov

4. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

   This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713.…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   New York University (NYU) Clinical Cancer Center, New York, New York

   Locations

   30 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07213791 on ClinicalTrials.gov

5. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

   The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, New York, New York

   Locations

   14 in total

   Run by

   Alterome Therapeutics, Inc.

   See if you can join NCT06835569 on ClinicalTrials.gov

6. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

   This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site 107, New York, New York

   Locations

   107 in total

   Run by

   DualityBio Inc.

   See if you can join NCT05914116 on ClinicalTrials.gov

7. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Irving Medical Center, New York, New York

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

8. Study of GS-2426 in Participants With Advanced Solid Tumors

   The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   6 in total

   Run by

   Gilead Sciences

   See if you can join NCT07601243 on ClinicalTrials.gov

9. A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

   This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center ( Site 0270), New York, New York

   Locations

   75 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT05067283 on ClinicalTrials.gov

10. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mount Sinai, New York, New York

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

11. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

    Stage

    Phase 2

    Ages

    12 and older

    Site

    Manhattan Eye, Ear, and Throat Hospital, New York, New York

    Locations

    181 in total

    Run by

    American Society of Clinical Oncology

    See if you can join NCT02693535 on ClinicalTrials.gov

12. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

    Locations

    9 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07349537 on ClinicalTrials.gov

13. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

    The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mount Sinai, New York, New York

    Locations

    20 in total

    Run by

    Tubulis GmbH

    See if you can join NCT06657222 on ClinicalTrials.gov

14. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

    The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    22 in total

    Run by

    Pyxis Oncology, Inc

    See if you can join NCT06795412 on ClinicalTrials.gov

15. First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

    This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura and Issac Perlmutter Cancer Center, New York, New York

    Locations

    12 in total

    Run by

    VelaVigo Bio Inc

    See if you can join NCT07700160 on ClinicalTrials.gov

16. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

    This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Locations

    17 in total

    Run by

    NextCure, Inc.

    See if you can join NCT06792552 on ClinicalTrials.gov

17. Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

    The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: * To assess the safety and tolerability of …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Cancer Center, New York, New York

    Locations

    8 in total

    Run by

    Gilead Sciences

    See if you can join NCT06167317 on ClinicalTrials.gov

18. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Locations

    15 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT05719558 on ClinicalTrials.gov

19. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Laura and Isaac Perlmutter Cancer Center, New York, New York

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

20. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

    The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    NYU Langone Health-Perlmutter Cancer Center, New York, New York

    Locations

    39 in total

    Run by

    ModernaTX, Inc.

    See if you can join NCT05533697 on ClinicalTrials.gov

21. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NYU Langone, New York, New York

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

22. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Perlmutter Cancer Center at NYU Langone Health, New York, New York

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

23. A Study of MGC028 in Participants With Advanced Solid Tumors

    The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants with relapsed or refractory, unresectable, locally ad…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Icahn School of Medicine at Mt. Sinai, New York, New York

    Locations

    7 in total

    Run by

    MacroGenics

    See if you can join NCT06723236 on ClinicalTrials.gov

24. A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

    The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center, New York, New York

    Locations

    4 in total

    Run by

    AskGene Pharma, Inc.

    See if you can join NCT05867420 on ClinicalTrials.gov